Literature DB >> 29674209

Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: A protective role for testosterone.

Hussein F Sakr1, Abdelaziz M Hussein2, Elsayed A Eid3, Mahmoud AlKhateeb4.   

Abstract

AIMS: To investigate the effects of testosterone (Test) deficiency and testosterone replacement therapy (TRT) on the development of non-alcoholic fatty liver disease (NAFLD) and associated peripheral insulin resistance (IR) in male rats and to illustrate the underlying mechanisms of action.
MATERIALS AND METHODS: male Sprague Dawley rats were divided into 3 groups as follows: 1) sham-operated group (n = 11), 2) ORCD-induced group (n = 9) exposed to orchidectomy (ORCD), achieved by complete surgical removal of testicles, and 3) ORCD + Test treated group (n = 10) (11 ng/mL Test propionate, 3x/week, S.C.).
RESULTS: Data revealed significant increases in final body, liver, visceral and subcutaneous fats weights with significant increases in fasting plasma glucose and insulin levels and HOMA-IR. Additionally, ORCD rats had higher UAC for measured glucose levels and insulin levels during OGTT and higher AUC for measured glucose levels during ITT. Interesting, higher serum and hepatic levels of TGs and CHOL and higher serum levels of LDL were seen in ORCD-induced rats. Mechanistically, significant increases in mRNA levels of SREBP-1, SREBP-2, ACC-1, FAS, HMGCOAR and HMGCOAS with significant increases in protein levels of both precursor and mature SREBP-1 and SREBP-2, PPAR-α, p-PPAR-α, CPT-1 and UCP-2 and significant lower protein levels p-AMPK and p-ACC-1 were detected in livers of ORCD rats. Test administration to ORCD-induced rats significantly ameliorated all of the above mentioned biochemical endpoints and reversed the effect of ORCD on mRNA and protein levels of these targets. In conclusion, Test deficiency could be an independent risk factor for the development of NAFLD by upregulation of lipid synthesis and disturb fatty acids oxidation whereas Test therapy is a protective strategy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fatty liver; Male hypogonadism; Orchidectomy; Testosterone

Mesh:

Substances:

Year:  2018        PMID: 29674209     DOI: 10.1016/j.steroids.2018.04.004

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  5 in total

1.  Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis.

Authors:  Man-Qiu Mo; Zi-Chun Huang; Zhen-Hua Yang; Yun-Hua Liao; Ning Xia; Ling Pan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-06-24       Impact factor: 4.435

2.  Fatty liver and alteration of the gut microbiome induced by diallyl disulfide.

Authors:  Yanhong Yang; Fei Yang; Miaoling Huang; Huijuan Wu; Changyuan Yang; Xinyue Zhang; Lanxiang Yang; Guibin Chen; Shuqi Li; Qianyu Wang; Shaomin Liu; Yanyan Liu; Yuting Lei; Zili Lei; Jiao Guo
Journal:  Int J Mol Med       Date:  2019-09-24       Impact factor: 4.101

Review 3.  Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Authors:  Madalena Von-Hafe; Marta Borges-Canha; Catarina Vale; Ana Rita Leite; João Sérgio Neves; Davide Carvalho; Adelino Leite-Moreira
Journal:  Metabolites       Date:  2022-03-29

Review 4.  Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm.

Authors:  Abdulmaged M Traish
Journal:  World J Mens Health       Date:  2020-03-20       Impact factor: 5.400

5.  Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men.

Authors:  E Maseroli; P Comeglio; C Corno; I Cellai; S Filippi; T Mello; A Galli; E Rapizzi; L Presenti; M C Truglia; F Lotti; E Facchiano; B Beltrame; M Lucchese; F Saad; G Rastrelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2020-08-08       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.